• 161
  • 105
  • Favorite

Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™

Tiger Newspress2021-06-15

Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.

“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”

“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.

“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment105

  • Coldfire
    ·2021-06-18
    Okie
    Reply
    Report
  • Coldfire
    ·2021-06-18
    Okie
    Reply
    Report
  • J___T
    ·2021-06-17
    K
    Reply
    Report
    Fold Replies
    • Coldfire
      Ok
      2021-06-18
      Reply
      Report
  • OO_898
    ·2021-06-17
    Good 
    Reply
    Report
  • HMian
    ·2021-06-17
    Some gain from this news!
    Reply
    Report
    Fold Replies
  • Albaakbert
    ·2021-06-17
    What a trick
    Reply
    Report
  • TidusChris
    ·2021-06-16
    Gogogo! 
    Reply
    Report
  • Alihuat
    ·2021-06-16
    Help and save the blind... 
    Reply
    Report
  • MLJY94
    ·2021-06-16
    Nice!
    Reply
    Report
  • Symph1
    ·2021-06-16
    Good
    Reply
    Report
  • HengHengUp
    ·2021-06-16
    wow 
    Reply
    Report
  • Skii
    ·2021-06-16
    Superb
    Reply
    Report
  • Robson
    ·2021-06-16
    Lai
    Reply
    Report
  • MarcusLiong
    ·2021-06-16
    Hahaha
    Reply
    Report
  • AmateurI
    ·2021-06-16
    Yes!
    Reply
    Report
  • RobinStocks
    ·2021-06-15
    Superb
    Reply
    Report
  • Cfgramos
    ·2021-06-15
    This is good news!
    Reply
    Report
  • ggTemple
    ·2021-06-15
    Good news wow!
    Reply
    Report
    Fold Replies
    • Xkuanx
      Yeh
      2021-06-15
      Reply
      Report
  • Jan9413
    ·2021-06-15
    [呆住] 
    Reply
    Report
  • Chengrent
    ·2021-06-15
    Amazing
    Reply
    Report
 
 
 
 

Most Discussed

 
 
 
 
 

7x24

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email:uservice@ttm.financial